(18 cycles total). For the treatment of HER2+ metastatic breast cancer, you will receive Perjeta and Herceptin until the medicine no longer controls your breast cancer or you have side effects that require you to stop treatment. You may receive other treatments with these medications.Continue ...
This is a patient friendly review of the cancer drug Herceptin (or, Trastuzumab), commonly used for HER2 positive breast cancer, often in conjuction with Perjeta (or Pertuzumab), even by injection (Phesgo); Herceptin can sometimes be used for stomach cancer or bowel cancer if the patient is ...
It should be stopped in patients receiving adjuvant therapy, and withheld in patients with metastatic cancer if the function of the heart decreases significantly. Herceptin (trasuzumab) side effects Common side effects include: Diarrhea(25% of patients) A prickling or burning sensation in the skin...
Perjeta is the 1st FDA-approved drug for the neoadjuvant treatment of breast cancer. Perjeta’s new indication is intended for patients with HER2-positive, locally advanced, inflammatory or early stage breast cancer (tumor greater than 2 cm in diameter or with positive lymph nodes) who are at ...